AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15024305 — intervention group
Group type: EXPERIMENTAL
Intervention: Open intraoperative RFA
Number of subjects: 608
Study 15024305 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous RFA
Number of subjects: 608
Study 15024305 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cirrhosis
Number of subjects: 608
Study 15024305 — intervention group
Group type: COMPARATOR
Intervention: Noncirrhotic patients
Number of subjects: 608
Study 15024305 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 608
Study 15024305 — intervention group
Group type: EXPERIMENTAL
Intervention: Late complications
Number of subjects: 608
Study 11435509 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental folic acid (15% [3',5'-(2)H(2)] folic acid) during days 1-41, unlabeled during days 42-84, total folate intake of 1.02 or 1.93 micromol/d (450 or 850 microg/d)
Number of subjects: 12
Study 9923412 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII concentrate, 70 units/kg within 24 hours of recognition of initial organ dysfunction followed by 50 units/kg 8, 16, 48, and 72 hours later
Number of subjects: 49
Study 9923412 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII concentrate
Number of subjects: 49
Study 8072258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) at a dosage of 5.54 ± 0.81 mg/kg/day for 12 to 60 months
Number of subjects: 36
Study 8072258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment continued for 12 to 60 months
Number of subjects: 36
Study 8072258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment with a dosage of up to 5.5 mg/kg/day
Number of subjects: 36
Study 8072258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment with a dosage greater than 5.5 mg/kg/day
Number of subjects: 36
Study 8072258 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive tapering of CsA after prolonged remission of more than one year
Number of subjects: 36
Study 3354625 — intervention group
Group type: EXPERIMENTAL
Intervention: Project group structure (subjects participate together on a common task)
Number of subjects: 41
Study 3354625 — intervention group
Group type: COMPARATOR
Intervention: Parallel group structure (subjects each have a task)
Number of subjects: 41
Study 3354625 — intervention group
Group type: EXPERIMENTAL
Intervention: Project group structure
Number of subjects: 41
Study 3354625 — intervention group
Group type: COMPARATOR
Intervention: Parallel group structure
Number of subjects: 41
Study 3354625 — intervention group
Group type: COMPARATOR
Intervention: Project group structure and Parallel group structure
Number of subjects: 41
Study 4886627 — intervention group
Group type: EXPERIMENTAL
Intervention: Short courses of nitrofurantoin
Number of subjects: 0
Study 4886627 — intervention group
Group type: EXPERIMENTAL
Intervention: Short courses of ampicillin
Number of subjects: 0
Study 4886627 — intervention group
Group type: COMPARATOR
Intervention: Untreated bacteriuric women
Number of subjects: 0
Study 4886627 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (nitrofurantoin or ampicillin)
Number of subjects: 0
Study 4886627 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfections post-treatment
Number of subjects: 0
Study 31194213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) tirofiban administration
Number of subjects: 95
Study 31194213 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) tirofiban administration
Number of subjects: 95
Study 29054911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib-lenalidomide-dexamethasone (IRd)
Number of subjects: 722
Study 29054911 — intervention group
Group type: COMPARATOR
Intervention: Placebo-lenalidomide-dexamethasone (placebo-Rd)
Number of subjects: 722
Study 26101306 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleCARE
Number of subjects: 481
Study 26101306 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure
Number of subjects: 481
Study 26101306 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleCARE (when cost was not a barrier)
Number of subjects: 481
Study 26101306 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleCARE (when cost was a barrier)
Number of subjects: 481
Study 23810433 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU intranasal oxytocin
Number of subjects: 0
Study 23810433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21576655 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 230
Study 21576655 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 230
Study 19260129 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with STIR
Number of subjects: 36
Study 19260129 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 36
Study 17101806 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence case management intervention with monetary reinforcement (CM)
Number of subjects: 90
Study 17101806 — intervention group
Group type: COMPARATOR
Intervention: Standard of care group (SC)
Number of subjects: 90
Study 15456520 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on day 1 and 8, and cisplatin (60 mg/m2 or 70 mg/m2 for older patients; 80 mg/m2 or 90 mg/m2 for younger patients) in 28-day cycles.
Number of subjects: 0
Study 10806139 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg four times a day)
Number of subjects: 34
Study 10806139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Terbutaline + Budesonide)
Number of subjects: 34
Study 10806139 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg twice a day)
Number of subjects: 34
Study 10806139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8773158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril at a dosage ratio of 5:1 (initially captopril 5 mg to lisinopril 1 mg)
Number of subjects: 56
Study 8773158 — intervention group
Group type: COMPARATOR
Intervention: Captopril (control group)
Number of subjects: 56
Study 8773158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost savings analysis
Number of subjects: 56
Study 1281103 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens extract (160 mg t.d.) for 3 months
Number of subjects: 35
Study 1281103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3912184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprolol (120, 240 and 480 mg)
Number of subjects: 6
Study 3912184 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40, 80 and 160 mg)
Number of subjects: 6
Study 3912184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29784589 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS at 2 mA (n=66, 31 active)
Number of subjects: 101
Study 29784589 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS at 3 mA (n=35, 20 active)
Number of subjects: 101
Study 29784589 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 101
Study 29784589 — intervention group
Group type: COMPARATOR
Intervention: Blinding assessment
Number of subjects: 101
Study 27886017 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive insoles
Number of subjects: 18
Study 27886017 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy twice a week
Number of subjects: 18
Study 25450133 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsensory vibratory noise stimulation at 70% of sensory threshold
Number of subjects: 12
Study 25450133 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsensory vibratory noise stimulation at 85% of sensory threshold
Number of subjects: 12
Study 23245226 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (10 sessions of behavioral risk reduction counseling)
Number of subjects: 4296
Study 22132216 — intervention group
Group type: COMPARATOR
Intervention: Clinician-supported (CL)
Number of subjects: 131
Study 22132216 — intervention group
Group type: COMPARATOR
Intervention: Coach-supported (CO)
Number of subjects: 131
Study 22132216 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study 18192700 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD(R)-pacing
Number of subjects: 50
Study 18192700 — intervention group
Group type: COMPARATOR
Intervention: AAI(R)-pacing
Number of subjects: 50
Study 16644616 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal approach
Number of subjects: 32
Study 16644616 — intervention group
Group type: COMPARATOR
Intervention: Scrotal approach
Number of subjects: 32
Study 16644616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 32
Study 14640990 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (5 microg/kg per day for 1 month and 10 microg/kg per day for 12-30 months)
Number of subjects: 0
Study 14640990 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 0
Study 10363394 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational seminars on generic drugs and computer‐produced prescribing feedback (Intervention group)
Number of subjects: 10
Study 10363394 — intervention group
Group type: COMPARATOR
Intervention: No seminars and no feedback (Control group)
Number of subjects: 10
Study 8537523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CT (DCT)
Number of subjects: 31
Study 8537523 — intervention group
Group type: COMPARATOR
Intervention: Spiral CT (SCT)
Number of subjects: 31
Study 1775612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate administration
Number of subjects: 48
Study 7009946 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 16913
Study 7009946 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16913
Study 31003210 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of craniopharyngiomas
Number of subjects: 71
Study 31003210 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Number of subjects: 71
Study 31003210 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment (SF-36)
Number of subjects: 71
Study 27767993 — intervention group
Group type: COMPARATOR
Intervention: Souvenaid (uridine monophosphate, docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium)
Number of subjects: 0
Study 27767993 — intervention group
Group type: COMPARATOR
Intervention: Souvenaid
Number of subjects: 0
Study 25748976 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR prompt (alert) indicating specific immunizations recommended at all office visits.
Number of subjects: 7040
Study 25748976 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff prompts (reminder sheet) placed on the provider's desk in the exam room.
Number of subjects: 7040
Study 25748976 — intervention group
Group type: COMPARATOR
Intervention: Provider prompts (EHR and staff prompts combined)
Number of subjects: 7040
Study 25439340 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 I.U. oxytocin
Number of subjects: 60
Study 25439340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22234017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg capsule orally 1 h before surgery
Number of subjects: 30
Study 22234017 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 30
Study 19237781 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous anterior chamber infusion using anterior chamber maintainer (ACM) with balanced salt solution (BSS)
Number of subjects: 50
Study 19237781 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmic viscosurgical device (OVD) with balanced salt solution (BSS)
Number of subjects: 50
Study 17425871 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/d)
Number of subjects: 120
Study 17425871 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (500 microg qd)
Number of subjects: 120
Study 17425871 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (500 microg qd) + Folic acid (5 mg/d)
Number of subjects: 120
Study 17425871 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 120
Study 15353917 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase plus abciximab
Number of subjects: 150
Study 15353917 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 150
Study 15353917 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase plus abciximab (within <2 hours)
Number of subjects: 150
Study 15353917 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (within <2 hours)
Number of subjects: 150
Study 15353917 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase plus abciximab (for time-to-admission intervals > or = 2 hours)
Number of subjects: 150
Study 15353917 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (for time-to-admission intervals > or = 2 hours)
Number of subjects: 150
Study 11576058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.15 mg/kg
Number of subjects: 60
Study 11576058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.22 mg/kg
Number of subjects: 60
Study 11576058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg/kg
Number of subjects: 60
Study 11576058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.11 mg/kg
Number of subjects: 60
Study 11576058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.21 mg/kg
Number of subjects: 60
Study 11576058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.25 mg/kg
Number of subjects: 60
Study 11576058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (various doses)
Number of subjects: 60
Study 9688391 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation with low-dose human menopausal gonadotrophin and intrauterine insemination (IUI) in stimulated cycles
Number of subjects: 74
Study 9688391 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI) in natural cycles
Number of subjects: 74
Study 9211571 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily
Number of subjects: 544
Study 9211571 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline 100 mg daily
Number of subjects: 544
Study 2017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 48
Study 2017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 48
Study 2017529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6124759 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐lymphocyte globulin, prednisolone, and azathioprine (3 mg/kg daily after 1 month)
Number of subjects: 43
Study 6124759 — intervention group
Group type: COMPARATOR
Intervention: placebo preparations
Number of subjects: 43
Study 30601982 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith, Activity, and Nutrition (FAN) program
Number of subjects: 54
Study 29048958 — intervention group
Group type: EXPERIMENTAL
Intervention: Shade sails at treatment PRAs
Number of subjects: 144
Study 29048958 — intervention group
Group type: COMPARATOR
Intervention: Control PRAs without shade sails
Number of subjects: 144
Study 29048958 — intervention group
Group type: EXPERIMENTAL
Intervention: Shade sails at treatment PRAs in Denver
Number of subjects: 144
Study 29048958 — intervention group
Group type: EXPERIMENTAL
Intervention: Shade sails at treatment PRAs in Melbourne
Number of subjects: 144
Study 25253583 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan plus CCB
Number of subjects: 5141
Study 25253583 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan plus diuretic
Number of subjects: 5141
Study 23647755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford and RTOG guidelines
Number of subjects: 11
Study 23647755 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan and SCALOP guidelines
Number of subjects: 11
Study 23647755 — intervention group
Group type: COMPARATOR
Intervention: PTV-based plans without eLNs
Number of subjects: 11
Study 23647755 — intervention group
Group type: EXPERIMENTAL
Intervention: All contouring guidelines
Number of subjects: 11
Study 21575941 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy
Number of subjects: 90
Study 21575941 — intervention group
Group type: COMPARATOR
Intervention: Laser vaporization
Number of subjects: 90
Study 18465345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 53418
Study 18465345 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 53418
Study 18465345 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 53418
Study 18465345 — intervention group
Group type: COMPARATOR
Intervention: Irradiated patients
Number of subjects: 53418
Study 18465345 — intervention group
Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 53418
Study 18465345 — intervention group
Group type: COMPARATOR
Intervention: Age at diagnosis
Number of subjects: 53418
Study 18465345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 53418
Study 17037267 — intervention group
Group type: COMPARATOR
Intervention: At least one dose vs. placebo
Number of subjects: 0
Study 17037267 — intervention group
Group type: COMPARATOR
Intervention: At least one dose vs. active control
Number of subjects: 0
Study 17037267 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12627416 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment at high dose
Number of subjects: 146
Study 12627416 — intervention group
Group type: COMPARATOR
Intervention: New treatment at low dose
Number of subjects: 146
Study 12627416 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 146
Study 12627416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 11148604 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen (95% O(2) + 5% CO(2))
Number of subjects: 16
Study 11148604 — intervention group
Group type: EXPERIMENTAL
Intervention: 92% O(2) + 8% CO(2)
Number of subjects: 16
Study 11148604 — intervention group
Group type: COMPARATOR
Intervention: 100% O(2)
Number of subjects: 16
Study 11148604 — intervention group
Group type: COMPARATOR
Intervention: 97% O(2) + 3% CO(2)
Number of subjects: 16
Study 8526696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 32
Study 8526696 — intervention group
Group type: COMPARATOR
Intervention: Oral quinidine sulfate (300 mg)
Number of subjects: 32
Study 8526696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone
Number of subjects: 32
Study 8526696 — intervention group
Group type: COMPARATOR
Intervention: Oral digoxin/quinidine
Number of subjects: 32
Study 8526696 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amiodarone and oral quinidine
Number of subjects: 32
Study 1984814 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 24
Study 1984814 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 24
Study 1984814 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and Salbutamol combined
Number of subjects: 24
Study 1984814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6404980 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based treatment
Number of subjects: 0
Study 6404980 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based treatment
Number of subjects: 0
Study 30248621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools with full implementation of the smoking prevention program
Number of subjects: 4161
Study 30248621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools with partial implementation of the smoking prevention program
Number of subjects: 4161
Study 30248621 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 4161
Study 28068613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT)
Number of subjects: 34
Study 28068613 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Therapy for Depression (BATD)
Number of subjects: 34
Study 28068613 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 34
Study 26304767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact immediate‐release/extended‐release oxycodone/acetaminophen 15/650 mg
Number of subjects: 61
Study 26304767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact immediate‐release/extended‐release oxycodone/acetaminophen 30/1,300 mg
Number of subjects: 61
Study 26304767 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed immediate‐release/extended‐release oxycodone/acetaminophen 30/1,300 mg
Number of subjects: 61
Study 26304767 — intervention group
Group type: COMPARATOR
Intervention: All subjective effects
Number of subjects: 61
Study 24803133 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 50
Study 24803133 — intervention group
Group type: COMPARATOR
Intervention: Cuffed tracheal tube
Number of subjects: 50
Study 22067270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 122
Study 22067270 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 122
Study 19172130 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy (20 mg/day elemental zinc for 14 days)
Number of subjects: 0
Study 19172130 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral rehydration solution and feeding advice without zinc)
Number of subjects: 0
Study 17982923 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (eicosapentaenoic acid and docosahexaenoic acid plus 10 mg vitamin E)
Number of subjects: 20
Study 17982923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15238051 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling Urge Questionnaire (GUS)
Number of subjects: 968
Study 12032413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (C)
Number of subjects: 17
Study 12032413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 17